BR112021015281A2 - Ácidos nucleicos recombinantes contendo sequências promotoras de alfa-herpesvírus - Google Patents

Ácidos nucleicos recombinantes contendo sequências promotoras de alfa-herpesvírus Download PDF

Info

Publication number
BR112021015281A2
BR112021015281A2 BR112021015281-4A BR112021015281A BR112021015281A2 BR 112021015281 A2 BR112021015281 A2 BR 112021015281A2 BR 112021015281 A BR112021015281 A BR 112021015281A BR 112021015281 A2 BR112021015281 A2 BR 112021015281A2
Authority
BR
Brazil
Prior art keywords
cell
seq
nucleic acid
acid sequence
promoter
Prior art date
Application number
BR112021015281-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Esteban Engel
Carola MATURANA
Lynn Enquist
Original Assignee
The Trustees Of Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Princeton University filed Critical The Trustees Of Princeton University
Publication of BR112021015281A2 publication Critical patent/BR112021015281A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
BR112021015281-4A 2019-02-05 2020-02-05 Ácidos nucleicos recombinantes contendo sequências promotoras de alfa-herpesvírus BR112021015281A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962801524P 2019-02-05 2019-02-05
US62/801,524 2019-02-05
US201962950848P 2019-12-19 2019-12-19
US62/950,848 2019-12-19
PCT/US2020/016787 WO2020163475A1 (en) 2019-02-05 2020-02-05 Recombinant nucleic acids containing alphaherpesvirus promoter sequences

Publications (1)

Publication Number Publication Date
BR112021015281A2 true BR112021015281A2 (pt) 2021-10-05

Family

ID=71947095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015281-4A BR112021015281A2 (pt) 2019-02-05 2020-02-05 Ácidos nucleicos recombinantes contendo sequências promotoras de alfa-herpesvírus

Country Status (11)

Country Link
US (1) US12551574B2 (cg-RX-API-DMAC7.html)
EP (1) EP3921431A4 (cg-RX-API-DMAC7.html)
JP (2) JP7658580B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210125014A (cg-RX-API-DMAC7.html)
CN (1) CN113383082A (cg-RX-API-DMAC7.html)
AU (1) AU2020218337A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015281A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127019A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009161A (cg-RX-API-DMAC7.html)
SG (1) SG11202108111WA (cg-RX-API-DMAC7.html)
WO (1) WO2020163475A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7658580B2 (ja) 2019-02-05 2025-04-08 ザ、トラスティーズ オブ プリンストン ユニバーシティ アルファヘルペスウイルスプロモーター配列を含む組換え核酸
US20250025575A1 (en) * 2021-11-23 2025-01-23 The Trustees Of Princeton University Compositions and Methods for Cell-Specific Expression of Target Genes
WO2026032009A1 (en) * 2024-08-06 2026-02-12 Chinese Institute For Brain Research, Beijing (Cibr) A microglia-specific regulatory element for aav-mediated transgene manipulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352596A (en) * 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US7341847B2 (en) * 2003-04-02 2008-03-11 Agency For Science, Technology And Research Promoter construct for gene expression in neuronal cells
WO2005080581A2 (en) * 2004-02-17 2005-09-01 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
JP7090548B2 (ja) 2016-01-29 2022-06-24 ジリオン バイオテック ゲーエムベーハー Aav系条件的発現系
JP7658580B2 (ja) 2019-02-05 2025-04-08 ザ、トラスティーズ オブ プリンストン ユニバーシティ アルファヘルペスウイルスプロモーター配列を含む組換え核酸
US20250025575A1 (en) 2021-11-23 2025-01-23 The Trustees Of Princeton University Compositions and Methods for Cell-Specific Expression of Target Genes

Also Published As

Publication number Publication date
EP3921431A1 (en) 2021-12-15
CA3127019A1 (en) 2020-08-13
JP7658580B2 (ja) 2025-04-08
WO2020163475A1 (en) 2020-08-13
JP2025026584A (ja) 2025-02-21
JP2022518867A (ja) 2022-03-16
EP3921431A4 (en) 2022-12-14
CN113383082A (zh) 2021-09-10
KR20210125014A (ko) 2021-10-15
MX2021009161A (es) 2021-09-10
US12551574B2 (en) 2026-02-17
SG11202108111WA (en) 2021-08-30
US20220378941A1 (en) 2022-12-01
AU2020218337A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US11117933B2 (en) Selective recovery
CN109641939B (zh) 变体腺伴随病毒及使用方法
ES2941502T3 (es) Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
JP2025026584A (ja) アルファヘルペスウイルスプロモーター配列を含む組換え核酸
ES2946512T3 (es) Terapia génica para el tratamiento de una enfermedad degenerativa de la retina
JP7624728B2 (ja) Dna結合ドメイントランスアクチベーター及びその使用
Maturana et al. Small alphaherpesvirus latency-associated promoters drive efficient and long-term transgene expression in the CNS
US20230279405A1 (en) Dna-binding domain transactivators and uses thereof
US20250025575A1 (en) Compositions and Methods for Cell-Specific Expression of Target Genes
Galvan et al. MiniPromoters Ple384 (TH) and Ple388 (PITX3) for targeting midbrain dopaminergic neurons in mice and monkeys
TWI883636B (zh) 含有星狀細胞導向啟動子構築體之合成核酸及其使用方法
WO2024017387A1 (en) Novel aav capsids for targeting nervous system and uses thereof
WO2024199478A1 (en) Variant aav9 capsid proteins and uses thereof
EA047753B1 (ru) Трансактиваторы днк-связывающего домена и их применение
HK40016209A (en) Selective recovery

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.